Chris played an important role in the formation of ADC Therapeutics in 2011 and has served on the company’s Board of Directors since its inception. He served as the company’s Chief Executive Officer from June 2015 until May 2022. He was also Co-Founder of Spirogen Ltd and its Chief Executive Officer leading up to the company’s sale to AstraZeneca in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Prior to the acquisition, Chris led numerous Spirogen collaboration transactions, including agreements with Genentech and Seattle Genetics. He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.